Could a ketone drink help fight colorectal cancer? a trial investigates

NCT ID NCT05338307

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study is testing whether a ketone supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people scheduled for a colonoscopy or flexible sigmoidoscopy as part of their standard care. Participants will take a drink containing R-1,3-butanediol three times daily for a short period. The main goals are to see if people can stick with the supplement and if it raises BHB levels in the blood, which could inform future research on its potential role in colorectal cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
R-1,3-Butanediol (a ketone supplement)
What this could lead to
If this supplement is well-tolerated and raises blood ketone levels, it could pave the way for larger studies exploring whether ketones might influence colorectal cancer development or progression.
What could go wrong
This is a very small, early feasibility study, not designed to test whether the supplement affects cancer itself. Side effects or poor tolerance could limit its use, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.